A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
Open accessThe DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
This phase I study was designed to examine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), the recommended dose (RD) for phase II, and the pharmacokinetics of NK105, a new polymeric micelle carrier system for paclitaxel (PTX). NK105 was administered as a 1-h intravenous infusion every 3 weeks, without antiallergic premedication. The starting dose was 10 mg m(-2), and the dose was escalated according to the accelerated titration method. Nineteen patients were recruited. The tumour types treated included pancreatic (n=11), bile duct (n=5), gastric (n=2), and colonic (n=1) cancers. Neutropenia was the most common haematological toxicity. A grade 3 fever developed in one patient given 180 mg m(-2). No other grades 3 or 4 nonhaematological toxicities, including neuropathy, was observed during the entire study period. DLTs occurred in two patients given 180 mg m(-2) (grade 4 neutropenia lasting for more than 5 days). Thus, this dose was designated as the MTD. Grade 2 hypersensitivity reactions developed in only one patient given 180 mg m(-2). A partial response was observed in one patient with pancreatic cancer. The maximum concentration (C(max)) and area under the concentration (AUC) of NK105 were dose dependent. The plasma AUC of NK105 at 150 mg m(-2) was approximately 15-fold higher than that of the conventional PTX formulation. NK105 was well tolerated, and the RD for the phase II study was determined to be 150 mg m(-2) every 3 weeks. The results of this phase I study warrant further clinical evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Some other paclitaxel polymeric micelle formulations, such NK105, were also reported to have lower toxicity in clinical trials compared to Taxol® [238].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [238]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a phase I trial of NK105, nineteen patients with various type of cancers (pancreatic, bile duct, gastric, and colonic) were recruited to examine the safety and PK of NK105. NK105 doses ranging from 10 mg/m2 to 180 mg/m2 was administered to patients without premedication. The MTD of NK105 was determined to be 180 mg/m2 due to dose limiting hematological toxicity (neutropenia). The PK profile of”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · cited 1×
“Tumour response was evaluated according to the Response Evaluation Criteria in Solid Tumors criteria (Therasse et al, 2000).”
MethodMatsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 2×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000; Duncan, 2003).”
BackgroundSelf-citationThe dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269 · cited 2×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000; Duncan, 2003).”
BackgroundGradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153 · cited 2×
“In this trial, Abraxane demonstrated significantly higher response rates, compared with standard PTX, and a significantly longer time to progression (Gradishar et al, 2005).”
BackgroundRowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924 · cited 1×
“However, the use of Cremophor EL is known to be associated with acute hypersensitivity reactions (Weiss et al, 1990; Rowinsky and Donehower, 1995; Kloover et al, 2004).”
BackgroundHypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174 · cited 1×
“However, the use of Cremophor EL is known to be associated with acute hypersensitivity reactions (Weiss et al, 1990; Rowinsky and Donehower, 1995; Kloover et al, 2004).”
BackgroundTaxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821 · cited 1×
“These preparations include Xyotax (polyglutamate-conjugated PTX; Singer et al, 2003; Boddy et al, 2005), Abraxane (PTX coated with albumin; Ibrahim et al, 2002; Deisai et al, 2003; Nyman et al, 2005), and Genexol-PM (a PTX micelle in which PTX has been simply solubilised; Kim et al, 2004).”
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Research works printed but not linked: 1
- Deisai N, Trieu V, Yao R (2003) Evidence of greater antitumor activity of Cremophor-free nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol, role of a novel albumin transporter mechanism. 26th Annual San Antonio Breast Cancer Symposium San Antonio, TX
Cited by
Items 101–200 of 312
Koide, H., Asai, T., Kato, H., Ando, H., Shiraishi, K., Yokoyama, M., & Oku, N. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.049 · Cited by 64
“At present, a number of polymeric micelles encapsulating anticancer drugs are proceeding to clinical studies (Matsumura et al., 2004; Matsumura, 2008; Hamaguchi et al., 2007;).”
BackgroundWang, Y., Wang, C., Gong, C., Wang, Y., Guo, G. F., Luo, F., & Qian, Z. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.05.015 · Cited by 63
Cyclodextrin nanoparticles for diagnosis and potential cancer therapy: A systematic review
Karthic, A., Roy, A., Lakkakula, J., Alghamdi, S. A., Shakoori, A. M., Babalghith, A. O., Emran, T. B., Sharma, R., Lima, C. M. G., Kim, B., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.984311 · Cited by 62
“Over the past 2 decades many nanoparticulate drug delivery systems have been under clinical trials for delivering diverse types of hydrophobic drugs and siRNA to treat human solid cancerous tumors (Hamaguchi et al., 2007; Plummer et al., 2011; Kato et al., 2012; Von Hoff et al., 2016).”
BackgroundSamarajeewa, S., Shrestha, R., Elsabahy, M., Karwa, A. S., Li, A., Zentay, R. P., Kostelc, J. G., Dorshow, R. B., & Wooley, K. L. (2013) · Molecular Pharmaceutics · doi:10.1021/mp3005897 · Cited by 61
RNA-based micelles: A novel platform for paclitaxel loading and delivery
Shu, Y., Yin, H., Rajabi, M., Li, H., Vieweger, M., Guo, S., Shu, D., & Guo, P. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.014 · Cited by 60
Block copolymer micelles as ocular drug delivery systems
Assiri, A. A., Glover, K., Mishra, D., Waite, D. T., Vora, L. K., & Thakur, R. R. S. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104098 · Cited by 59
Polymeric micelles for cancer therapy: 3 C’s to enhance efficacy
Talelli, M., Rijcken, C. J. F., Hennink, W. E., & Lammers, T. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2012.10.003 · Cited by 58
Bridging cancer biology and the patients' needs with nanotechnology-based approaches
Fonseca, N. A., Gregório, A. C., Valério-Fernandes, Â., Simões, S., & Moreira, J. N. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.002 · Cited by 58
“Currently, there are multiple micellar formulations under investigation and in clinical trials such as: NK 911 [74], NK 105 [75], SP1049C [76] and Genexol-PM.”
BackgroundNanomedicine Reimagined: Translational Strategies for Precision Tumor Theranostics
Wu, Q., Yao, X., Duan, X., Chen, X. S., & Zhang, J. (2025) · Advanced Materials · doi:10.1002/adma.202510293 · Cited by 57
Applications of Nanotechnology in Cancer: A Literature Review of Imaging and Treatment
Narayana, A. (2014) · Journal of Nuclear Medicine & Radiation Therapy · doi:10.4172/2155-9619.1000195 · Cited by 57
“The percentage of liquid-phase lipids included can affect the dimension and surface morphology of particles and the acid concentration controls the initial rate of drug release [38].”
The potential of polymeric micelles in the context of glioblastoma therapy
Morshed, R. A., Cheng, Y., Auffinger, B., Wegscheid, M. L., & Lesniak, M. S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00157 · Cited by 55
“In a phase I clinical study, Hamaguchi et al. (2007) looked at treatment with NK105 in pancreatic, bile duct, and colon cancer.”
BackgroundHoang, B., Ekdawi, S. N., Reilly, R. M., & Allen, C. J. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400315p · Cited by 54
Self-assembling polymer systems for advanced treatment of cancer and inflammation
Palao‐Suay, R., Gómez‐Mascaraque, L. G., Aguilar, M. R., Vázquez‐Lasa, B., & Román, J. S. (2015) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2015.07.005 · Cited by 53
Current taxane formulations and emerging cabazitaxel delivery systems
Sun, B., Straubinger, R. M., & Lovell, J. F. (2018) · Nano Research · doi:10.1007/s12274-018-2171-0 · Cited by 53
Micelles as potential drug delivery systems for colorectal cancer treatment
Fatfat, Z., Fatfat, M., & Gali‐Muhtasib, H. U. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i25.2867 · Cited by 52
Integrating nanomedicine into clinical radiotherapy regimens
DuRoss, A. N., Neufeld, M. J., Rana, S. R., Thomas, C. R., & Sun, C. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.002 · Cited by 52
Polymeric micelles: a ray of hope among new drug delivery systems
Kapse, A., Anup, N., Patel, V., Saraogi, G. K., Mishra, D. K., & Tekade, R. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814487-9.00006-5 · Cited by 51
Liu, M., Chen, W., Zhang, X., Su, P., Yue, F., Zeng, S., & Du, S. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105373 · Cited by 50
Channa, G. M., Hassan, D., Ruiz-Pulido, G., Pourmadadi, M., Eshaghi, M. M., Behzadmehr, R., Tehrani, F. S., Rahdar, A., Medina, D. I., & Pandey, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104494 · Cited by 50
Gong, C., Wang, Y., Wang, X., Wei, X., Wu, Q., Wang, B., Dong, P., Chen, L., Luo, F., & Qian, Z. (2010) · Journal of Nanoparticle Research · doi:10.1007/s11051-010-0071-7 · Cited by 50
“Poly(ethylene glycol) (PEG) and poly(e-caprolactone) (PCL) are both biocompatible and have been used in several FDA-approved products (Hamaguchi et al. 2007; Kissel et al. 2002; Nakanishi et al. 2001; Zentner et al. 2001).”
BackgroundNunziata, G., Borroni, A., & Rossi, F. (2025) · Chemical Engineering Journal Advances · doi:10.1016/j.ceja.2025.100759 · Cited by 49
Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics
Yang, D., Yu, L., & Van, S. (2010) · Cancers · doi:10.3390/cancers3010017 · Cited by 49
“Surprisingly, the paclitaxel AUC and peak concentration of NK105 [27] were exceptionally high compared with those of Taxol [33] and Genexol-PM [26].”
BackgroundResultInfluentialTargeted Drug Delivery Systems for Pancreatic Cancer
Khare, V. R., Alam, N., Saneja, A., Dubey, R. D., & Gupta, P. N. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.2036 · Cited by 48
Nanotechnologies for Noninvasive Measurement of Drug Release
Moore, T. L., Chen, H., Morrison, R. A., Wang, F., Anker, J. N., & Alexis, F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400419k · Cited by 48
Synthesis and Self-Assembly of RGD-Functionalized PEO-PB Amphiphiles
Zupancich, J. A., Bates, F. S., & Hillmyer, M. A. (2009) · Biomacromolecules · doi:10.1021/bm900149b · Cited by 41
Caron, W. P., Morgan, K. P., Zamboni, B. A., & Zamboni, W. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3649 · Cited by 48
Kim, J., Yoon, H. J., Kim, S., Wang, K., Ishii, T., Kim, Y. R., & Jang, W. (2009) · Journal of Materials Chemistry · doi:10.1039/b904224e · Cited by 47
Emoto, S., Yamaguchi, H., Kishikawa, J., Yamashita, H., Ishigami, H., & Kitayama, J. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02274.x · Cited by 45
Development of Electrochromic Devices
Pawlicka, A. (2009) · Recent Patents on Nanotechnology · doi:10.2174/187221009789177821 · Cited by 44
Miller, T., Hill, A., Uezguen, S., Weigandt, M., & Goepferich, A. (2012) · Biomacromolecules · doi:10.1021/bm3002045 · Cited by 37
Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma
Li, J., Liu, F., Gupta, S. K., & Li, C. (2016) · Theranostics · doi:10.7150/thno.15122 · Cited by 44
Photo-controlled release of paclitaxel and model drugs from RNA pyramids
Xu, C., Li, H., Zhang, K., Binzel, D. W., Yin, H., Chiu, W., & Guo, P. (2018) · Nano Research · doi:10.1007/s12274-018-2174-x · Cited by 42
Zhang, J., Li, S., & Li, X. (2009) · Recent Patents on Nanotechnology · doi:10.2174/187221009789177803 · Cited by 42
Yasunaga, M., Furuta, M., Ogata, K., Koga, Y., Yamamoto, Y., Takigahira, M., & Matsumura, Y. (2013) · Scientific Reports · doi:10.1038/srep03050 · Cited by 41
Self-citationAu, M., Emeto, T. I., Power, J., Vangaveti, V., & Lai, H. C. (2016) · Biomedicines · doi:10.3390/biomedicines4030020 · Cited by 41
“Two studies (20%) did not state the median survival time, or the follow-up period [44,46] (see Tables 1 and 2).”
BackgroundInfluentialCao, Y., Liu, M., Zhang, K., Zu, G., Kuang, Y., Tong, X., Xiong, D., & Pei, R. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b01437 · Cited by 41
Yamamoto, Y., Hyodo, I., Koga, Y., Tsumura, R., Sato, R., Obonai, T., Fuchigami, H., Furuya, F., Yasunaga, M., Harada, M., et al. (2015) · Cancer Science · doi:10.1111/cas.12645 · Cited by 40
Self-citationvan Eerden, R. A. G., Mathijssen, R. H. J., & Koolen, S. L. W. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s272529 · Cited by 40
“The safety profile of NK105 was roughly the same compared to conventional paclitaxel.(86,87) The incidence of neuropathy was significantly lower after NK105 administration, while no differences were seen in hematological toxicity.”
BackgroundDrug Delivery Using Nanocarriers: Indian Perspective
Gupta, S., & Kumar, P. (2012) · Proceedings of the National Academy of Sciences India Section B Biological Sciences · doi:10.1007/s40011-012-0080-7 · Cited by 39
“Alternatively, micellar based drugs containing doxorubicin, paclitaxel, or cisplatin are in various stages of clinical trials [208–210].”
Mukai, H., Kato, K., Esaki, T., Ohsumi, S., Hozomi, Y., Matsubara, N., Hamaguchi, T., Matsumura, Y., Goda, R., Hirai, T., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0381-4 · Cited by 37
Self-citationNanodevices for studying nano-pathophysiology
Cabral, H., Miyata, K., & Kishimura, A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.06.003 · Cited by 36
Seki, T., Fang, J. Q., & Maeda, H. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6_3 · Cited by 36
Serras, A. S., Faustino, C. M. C., & Pinheiro, L. M. V. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081047 · Cited by 35
A simple method to improve the stability of docetaxel micelles
Zhang, L., Tan, L., Chen, L., Chen, X., Long, C., Peng, J., & Qian, Z. (2016) · Scientific Reports · doi:10.1038/srep36957 · Cited by 35
Fonge, H., Lee, H., Reilly, R. M., & Allen, C. J. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900201v · Cited by 34
Novozym 435‐Catalyzed Syntheses of Polyesters and Polyamides of Medicinal and Industrial Relevance
Khan, A., Sharma, S. K., Kumar, A., Watterson, A. C., Kumar, J., & Parmar, V. S. (2014) · ChemSusChem · doi:10.1002/cssc.201300343 · Cited by 33
Histological study on side effects and tumor targeting of a block copolymer micelle on rats
Kawaguchi, T., Honda, T., Nishihara, M., Yamamoto, T., & Yokoyama, M. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.02.011 · Cited by 33
Zhang, F., Khan, S. A., Li, R., Smolen, J. A., Zhang, S., Zhu, G., Su, L., Jahnke, A. A., Elsabahy, M., Chen, X. S., et al. (2017) · Nanoscale · doi:10.1039/c7nr05935c · Cited by 32
Liu, M., Fu, J., Li, J., Wang, L., Tan, Q., Ren, X., Peng, Z., & Zeng, H. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.001 · Cited by 32
Sakai‐Kato, K., Ishikura, K., Oshima, Y., Tada, M., Suzuki, T., Ishii‐Watabe, A., Yamaguchi, T., Nishiyama, N., Kataoka, K., Kawanishi, T., et al. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.12.022 · Cited by 30
Extracellular stability of nanoparticulate drug carriers
Liu, K. C., & Yeo, Y. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0286-0 · Cited by 29
“conjugate NPs) show greater t1/2 and/or AUC (Hamaguchi et al. 2007; Ernsting et al. 2012), providing better effects on primary tumors or metastasis in animal models (Ernsting et al.”
BackgroundInfluentialAraki, T., Kono, Y., Ogawara, K., Watanabe, T., Ono, T., Kimura, T., & Higaki, K. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-0020 · Cited by 29
Takemoto, H., Inaba, T., Nomoto, T., Matsui, M., Liu, X., Toyoda, M., Honda, Y., Taniwaki, K., Yamada, N., Kim, J., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119804 · Cited by 29
Polymeric Micelles for Drug Delivery
Wu, W., & Jiang, X. (2016) · Wiley eBooks · doi:10.1002/9783527694396.ch3 · Cited by 28
Innovative strategies for effective paclitaxel delivery: Recent developments and prospects
Wileński, S., Koper, A., Śledzińska, P., Bebyn, M. G., & Koper, K. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231208978 · Cited by 28
Yokosawa, M., Sonoda, Y., Sugiyama, S., Saito, R., Yamashita, Y., Nishihara, M., Satoh, T., Kumabe, T., Yokoyama, M., & Tominaga, T. (2010) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.221.257 · Cited by 28
“Various micelle-encapsulated cytotoxic agents are currently undergoing clinical evaluation for systemic administration, including doxorubicin (Tsukioka et al. 2002), paclitaxel (Hamaguchi et al. 2007), cisplatin (Uchino et al. 2005), and a camptothecin derivative SN-38 (Koizumi et al. 2006).”
BackgroundNakamura, I., Ichimura, E., Goda, R., Hayashi, H. D., Mashiba, H., Nagai, D., Yokoyama, H., Onda, T., & Masuda, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s114356 · Cited by 28
Advances in Predictive, Preventive and Personalised Medicine
Karabulut, S. (2012) · Cited by 27
Summer, M., Hussain, T., Ali, S., Khan, R. R. M., Muhammad, G., & Liaqat, I. (2024) · International Journal of Polymeric Materials · doi:10.1080/00914037.2024.2375337 · Cited by 27
“Paclitaxel is a member of the taxane anti-microtubular medication class that has demonstrated significant efficacy in the treatment of cancer by specifically targeting the microtubule subunit of tubulin [112] .”
Harada, Y., Yamamoto, T., Sakai, M., Saiki, T., Kawano, K., Maitani, Y., & Yokoyama, M. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.11.016 · Cited by 27
“Presently, five clinical trials are underway for tumor targeting with polymeric micelle systems (Matsumura et al., 2004; Hamaguchi et al., 2005; Koizumi et al., 2006; Hamaguchi et al., 2007; Nakajima et al., 2008a,b).”
BackgroundFluorescence Imaging Enabled Biodegradable Photostable Polymeric Micelles
Gyawali, D., Zhou, S., Tran, R. T., Zhang, Y., Liu, C., Bai, X., & Yang, J. Y. (2013) · Advanced Healthcare Materials · doi:10.1002/adhm.201300145 · Cited by 27
Polymer Micelles for Drug Delivery
Kim, S., & Park, K. (2010) · CRC Press eBooks · doi:10.1201/9781420087734-c19 · Cited by 27
Effects of stability of PEGylated micelles on the accelerated blood clearance phenomenon
Su, Y., Liu, M., Xiong, Y., Ding, J., Liu, X., Song, Y., & Deng, Y. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0588-3 · Cited by 27
Rasouli, M., Fallah, N., & Bekeschus, S. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/2990326 · Cited by 24
“Pancreatic cancer NK105 (a paclitaxel-incorporating micellar nanoparticle) Partial response observed in 1 out of 11 patients, significant myelosuppression not observed up to 80mg/m, pain or local toxicity in the area of the injection not observed in any patient, and 10 patients did not experience any hypersensitivity…”
BackgroundPhillips, M. C., & Mousa, S. A. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0361 · Cited by 24
Platinum in Biomedical Applications
Sinitsyna, O. V., Paralikar, P., Pandit, R., & Rai, M. K. (2018) · Springer eBooks · doi:10.1007/978-3-319-74814-6_7 · Cited by 22
Alshememry, A. K., Alsaleh, N. B., Alkhudair, N. A., Alzhrani, R. M., & Alshamsan, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.933457 · Cited by 22
“, 2007 (Hamaguchi et al., 2007) NK105 (PTXpolymeric micelles) Phase I Initially given 10 mg/m(2) and successively increased the dose NA The size of liver mets reduced by 90% in patients receiving a dose of 150 mg/m(2) or higher dose”
BackgroundTheranostic nanoparticles for detection and treatment of pancreatic cancer
Agarwal, H., Bynum, R. C., Saleh, N., Harris, D., MacCuaig, W. M., Kim, V., Sanderson, E. J., Dennahy, I. S., Singh, R., Behkam, B., et al. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1983 · Cited by 21
Nanomedicine: pharmacological perspectives
Bhattacharya, S., Alkharfy, K. M., Janardhanan, R., & Mukhopadhyay, D. (2012) · Nanotechnology Reviews · doi:10.1515/ntrev-2011-0010 · Cited by 21
“The safety of vehicles prepared using these agents may further facilitate their development for use in a variety of highly morbid and mortality causing diseases [92, 93] .”
BackgroundThe Role of Payload Hydrophobicity in Nanotherapeutic Pharmacokinetics
Norvaišas, P., & Žiemys, A. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23996 · Cited by 21
Proteins and Poly(Amino Acids)
Saxena, T. K., Karumbaiah, L., & Valmikinathan, C. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396983-5.00003-x · Cited by 21
Yang, Y., Bteich, J., & Li, S. (2016) · The AAPS Journal · doi:10.1208/s12248-016-0014-z · Cited by 20
Protein-based nanocarriers for paclitaxel (PTX) delivery in cancer treatment: A review
Abbaspour, S., Mohamadzadeh, M., & Shojaosadati, S. A. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143068 · Cited by 19
Block copolymer micelles as long-circulating drug vehicles
Patha, A. S., Patil, T., Pandey, P. K., Kuche, K., Ghadi, R., & Jain, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91248-8.00008-8 · Cited by 19
Kano, M. R., Harada, Iwata, Saito, Ishii, I., Hayashi, K., Yashiro, Hirakawa, Miyazono, Kato, et al. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s31247 · Cited by 19
Dual Acting Polymeric Nano-Aggregates for Liver Cancer Therapy
Al-Shakarchi, W., Alsuraifi, A., Curtis, A. D. M., & Hoskins, C. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020063 · Cited by 19
“PTX is a member of the taxane anti-microtubule drug family, which has exhibited a potent effect in cancer treatment by targeting the β-tubulin subunit of the microtubule [15].”
BackgroundUltrasound-Mediated Cancer Therapeutics Delivery using Micelles and Liposomes: A Review
Mukhopadhyay, D., Sano, C., AlSawaftah, N., El‐Awady, R., Husseini, G. A., & Paul, V. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892816666210706155110 · Cited by 18
Wani, F. A., Behera, K., & Patel, R. (2022) · ChemistrySelect · doi:10.1002/slct.202201928 · Cited by 18
Mundra, V., Peng, Y., Kumar, V., Li, W., Miller, D. D., & Mahato, R. I. (2015) · Drug Delivery and Translational Research · doi:10.1007/s13346-015-0226-2 · Cited by 18
“However, prolonged administration of drugs using cosolvents as a solubilizing agent is associated with hemolysis and acute hypersensitivity due to cosolvents which require administration of antihistamines and steroids [11, 12].”
A Review On Polymeric Micellar Nanocarriers
Dhembre, G. N., & Kshirsagar, R. V. (2011) · International Journal of Pharma and Bio Sciences · Cited by 18
Polymeric capsules and micelles as promising carriers of anticancer drugs
Kubiak, T. (2022) · Polymers in Medicine · doi:10.17219/pim/145513 · Cited by 17
Yang, X., Cao, D., Wang, N., Sun, L., Li, L., Nie, S., Wu, Q., Liu, X., Cheng, Y., & Gong, C. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23800 · Cited by 17
Nanovector-based therapies in advanced pancreatic cancer.
Tsai, C.-S., Park, J. W., & Chen, L. (2011) · PubMed Central · doi:10.3978/j.issn.2078-6891.2011.034 · Cited by 16
“Of them, NC-6004 is currently evaluated in a phase Ib/II trial for patients with advanced pancreatic cancer, and will be discussed (38-41).”
BackgroundNanoparticle-assisted Therapeutic Strategies for Effective Cancer Management
Nandi, D., Sharma, A., & Prabhakar, P. K. (2019) · Current Nanoscience · doi:10.2174/1573413715666190206151757 · Cited by 16
Vasilakes, A. L., Dziubla, T. D., & Wattamwar, P. P. (2013) · Wiley eBooks · doi:10.1002/9781118747896.ch5 · Cited by 15
Recent Advances on Pt-Based Compounds for Theranostic Applications
Ferrari, G., Lopez-Martinez, I., Wanek, T., Kuntner, C., & Montagner, D. (2024) · Molecules · doi:10.3390/molecules29153453 · Cited by 14
Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application
Egusquiaguirre, S. P., Pedraz, J. L., Hernández, R. M., & Igartua, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-47347-7.00029-x · Cited by 14
Faisal, K. S., Clulow, A. J., Krasowska, M., Gillam, T. A., Miklavcic, S. J., Williamson, N. H., & Blencowe, A. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.08.084 · Cited by 14
Mittal, A., & Chitkara, D. (2016) · Therapeutic Delivery · doi:10.4155/tde.15.90 · Cited by 14
Xiong, G., Schätzlein, A. G., & Uchegbu, I. F. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113632 · Cited by 13
Balaure, P. C., & Grumezescu, A. M. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140304103437 · Cited by 13
Clinical applications of nanostructured drug delivery systems
Mendes, M., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-102198-9.00004-1 · Cited by 13
Asakura, T., Yokoyama, M., SHIRAISHI, K., Aoki, K., & Ohkawa, K. (2018) · Anticancer Research · doi:10.21873/anticanres.12353 · Cited by 12
Sawdon, A. J., Zhang, J., Wang, X., & Peng, C. (2018) · Nanomaterials · doi:10.3390/nano8121041 · Cited by 12
van Gaal, E. V. B., & Crommelin, D. J. A. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-16241-6_2 · Cited by 12
Drug delivery applications of injectable biomaterials
Overstreet, D. J., von Recum, H. A., & Vernon, B. L. (2011) · Elsevier eBooks · doi:10.1533/9780857091376.2.95 · Cited by 12
Kurita, N., Shimada, M., Iwata, T., Nishioka, M., Morimoto, S., Yoshikawa, K., Higashijima, J., Miyatani, T., & Nakao, T. (2011) · The Journal of Medical Investigation · doi:10.2152/jmi.58.134 · Cited by 12
Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems
Bryaskova, R. G., Staykov, K., & Ganchev, D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020177 · Cited by 11
Megha, K. B., Swathi, S., Joseph, X., Vandana, U., & Mohanan, P. V. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-20925-4 · Cited by 11
“Due to the potential biological modifying properties and prominent cytotoxicity can provide better effects for anticancer drugs (Danson et al. 2004; Hamaguchi et al. 2007; Matsumura 2007).”
BackgroundLipid Spheres as Attractive Nanoscale Drug Delivery Platforms for Cancer Therapy
Uckun, F. M. (2011) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000128 · Cited by 11
“One ABC drug delivery formulation made of polyethylene glycol and polypropylene glycol block copolymers (PEO-PPO-PEO) has been in clinical trial [26] whereas several new generation ABCs have either received regulatory approval or entered proof-of-principle clinical testing [27-31].”
Background
Metadata
- Authors
- Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., Shimada, Y., Nakahama, H., & Matsumura, Y.
- Affiliations
- National Cancer Center Hospital (JP)
- National Cancer Center Hospital East (JP)
- Corresponding author
- Hamaguchi, T
- ORCID
- Venue
- British Journal of Cancer
- Published
- 2007-06-26
- Volume
- 97
- Issue
- 2
- Pages
- 170-176
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2360299
- OpenAlex
- W1990869510
- Cited by
- 290
- References
- 24
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 10 · 2023: 5 · 2022: 13 · 2021: 10 · 2020: 16 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 18 · 2015: 23 · 2014: 29 · 2013: 29 · 2012: 22
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- paclitaxel, polymeric micelles, maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, neutropenia, hypersensitivity, pancreatic cancer, cholangiocarcinoma, gastric cancer, colon cancer, accelerated titration
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Phytogenic, Digestive System Neoplasms, Female, Humans, Male, Micelles, Middle Aged, Tomography, X-Ray Computed, Paclitaxel, Maximum Tolerated Dose, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.